Analyses on the Impact of Tumor Burden at Progression and Changes in IMDC Risk Scores in the CLEAR Trial Prognostic Insights in Advanced RCC With Lenvatinib Plus Pembrolizumab : Episode 1

CLEAR Trial Insights on Lenvatinib Plus Pembrolizumab: Depth of Response and Clinical Outcomes in Advanced RCC

March 10, 2025

By Hans Hammers, MD, PhD
Thomas Hutson, DO, PharmD, PhD, FACP

Opinion

Video

Experts discuss insights from the CLEAR trial on lenvatinib plus pembrolizumab, focusing on depth of response and clinical outcomes in advanced renal cell carcinoma.

Now Viewing

EP: 1.CLEAR Trial Insights on Lenvatinib Plus Pembrolizumab: Depth of Response and Clinical Outcomes in Advanced RCC

EP: 2.Tumor Burden Impact on Postprogression Survival: Optimizing Strategies for Maximum Response in RCC

EP: 3.From Initial Response to Long-Term Outcomes: Optimizing RCC Treatment Strategies Across the Care Continuum

EP: 4.From IMDC Risk Assessments to Sequencing Strategies: Clinical Implications From CLEAR Post Hoc Analyses

EP: 5.Risk Score Stability and Post Lenvatinib Plus Pembrolizumab Treatment Selection in RCC

EP: 6.Clinical Pearls: Synthesizing Risk Assessment and Response Patterns in Advanced RCC Management

EP: 7.IO-IO vs IO-TKI: Expert Approaches to First-Line RCC Treatment Selection

EP: 8.KEYMAKER-U03: Lenvatinib Plus Belzutifan Emerges as a Promising Option in Advanced RCC and New Directions From ASCO GU 2025

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!